Pharmacokinetic profiles of biphasic insulin aspart 30/70 and 70/30 in patients with Type 1 diabetes: a randomized double-blinded crossover study

What Was Tested

The paper reports a study of Insulin Aspart, published as a randomized controlled trial.

Who Took Part

According to the abstract, 22 patients were involved.

PubMed indexes the participants as adults and middle-aged adults, both men and women.

A total of 22 patients with Type 1 diabetes (nine women, 13 men) aged 41.4 +/- 9.9 years (mean +/- sd) with a diabetes duration of 18.9 (2.3-40.3) years (median and range) completed the randomized, double-blinded, two-period crossover study.

On day 1 and day 15 of each treatment period, 24-h serum insulin and glucose profiles were evaluated.

How the Study Was Run

The design is described as randomized, double-blind and crossover.

Because people in this Insulin Aspart study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the patients nor the staff measuring them knew who was on Insulin Aspart, so expectations could not easily colour the readings.

In the crossover set-up each of the patients took both Insulin Aspart and the comparison in turn, acting as their own control.

Total area under the insulin aspart concentration-time curve (AUC(0-24 h)), AUC after dinner administration stratified into early (AUCdinner(0-6 h)) and intermediate-phase (AUCdinner(6-14 h)), maximum insulin concentration (Cmax), time to maximum insulin concentration (Tmax) after each meal were recorded.

What Was Measured

Topics PubMed links to this paper include Area Under Curve, Biphasic Insulins, Diabetes Mellitus, Type 1, Insulin, Insulin Aspart and Insulin, Isophane.

What This Means in Plain Language

The paper is a randomized, double-blind and crossover study of Insulin Aspart in 22 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2005 (Diabetic medicine : a journal of the British Diabetic Association), a journal based in England.

More context: the Insulin Aspart compound page.